VISTA is an acidic pH-selective ligand for PSGL-1.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
10 2019
Historique:
received: 25 10 2018
accepted: 20 09 2019
entrez: 25 10 2019
pubmed: 28 10 2019
medline: 20 11 2019
Statut: ppublish

Résumé

Co-inhibitory immune receptors can contribute to T cell dysfunction in patients with cancer

Identifiants

pubmed: 31645726
doi: 10.1038/s41586-019-1674-5
pii: 10.1038/s41586-019-1674-5
doi:

Substances chimiques

Antibodies, Blocking 0
B7 Antigens 0
Epitopes, B-Lymphocyte 0
Ligands 0
Membrane Glycoproteins 0
P-selectin ligand protein 0
Programmed Cell Death 1 Receptor 0
VSIR protein, human 0
Histidine 4QD397987E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

565-570

Références

Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).
pubmed: 29634943
McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).
pubmed: 30676822
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
pubmed: 29567705
Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).
pubmed: 21383057 pmcid: 3058578
Flies, D. B., Wang, S., Xu, H. & Chen, L. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537–1541 (2011).
pubmed: 21768399 pmcid: 3150865
Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).
pubmed: 28346412 pmcid: 5466900
Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl Acad. Sci. USA 116, 1692–1697 (2019).
pubmed: 30635425
Le Mercier, I. et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 74, 1933–1944 (2014).
pubmed: 24691994
Lines, J. L. et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74, 1924–1932 (2014).
pubmed: 24691993 pmcid: 3979527
Wang, L. et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc. Natl Acad. Sci. USA 111, 14846–14851 (2014).
pubmed: 25267631
Liu, J. et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl Acad. Sci. USA 112, 6682–6687 (2015).
pubmed: 25964334
Ceeraz, S. et al. VISTA deficiency accelerates the development of fatal murine lupus nephritis. Arthritis Rheumatol. 69, 814–825 (2017).
pubmed: 27992697 pmcid: 5723399
Li, N. et al. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci. Rep. 7, 1485 (2017).
pubmed: 28469254 pmcid: 5431161
Sergent, P. A. et al. Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female mice. Lupus 27, 210–216 (2018).
pubmed: 28659048
Kakavand, H. et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod. Pathol. 30, 1666–1676 (2017).
pubmed: 28776578
Schönichen, A., Webb, B. A., Jacobson, M. P. & Barber, D. L. Considering protonation as a posttranslational modification regulating protein structure and function. Annu. Rev. Biophys. 42, 289–314 (2013).
pubmed: 23451893 pmcid: 4041481
Wike-Hooley, J. L., Haveman, J. & Reinhold, H. S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2, 343–366 (1984).
pubmed: 6097949
Kato, Y. et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 13, 89 (2013).
pubmed: 24004445 pmcid: 3849184
Frei, A. P. et al. Direct identification of ligand-receptor interactions on living cells and tissues. Nat. Biotechnol. 30, 997–1001 (2012).
pubmed: 22983091
Carlow, D. A. et al. PSGL-1 function in immunity and steady state homeostasis. Immunol. Rev. 230, 75–96 (2009).
pubmed: 19594630
Abadier, M. & Ley, K. P-selectin glycoprotein ligand-1 in T cells. Curr. Opin. Hematol. 24, 265–273 (2017).
pubmed: 28178038
Matsumoto, M., Miyasaka, M. & Hirata, T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J. Immunol. 183, 7204–7211 (2009).
pubmed: 19890058
Pérez-Frías, A. et al. Development of an autoimmune syndrome affecting the skin and internal organs in P-selectin glycoprotein ligand 1 leukocyte receptor-deficient mice. Arthritis Rheumatol. 66, 3178–3189 (2014).
pubmed: 25132671
Tinoco, R. et al. PSGL-1 is an immune checkpoint regulator that promotes T Cell exhaustion. Immunity 44, 1190–1203 (2016).
pubmed: 27192578 pmcid: 4908967
Urzainqui, A. et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J. Immunol. 179, 7457–7465 (2007).
pubmed: 18025190
Nuñez-Andrade, N. et al. P-selectin glycoprotein ligand-1 modulates immune inflammatory responses in the enteric lamina propria. J. Pathol. 224, 212–221 (2011).
pubmed: 21432853
Veerman, K. M. et al. PSGL-1 regulates the migration and proliferation of CD8
pubmed: 22250093
Angiari, S. et al. Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. J. Immunol. 191, 5489–5500 (2013).
pubmed: 24174617 pmcid: 4627945
Sako, D. et al. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 83, 323–331 (1995).
pubmed: 7585949
Nelson, R. M. et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82, 3253–3258 (1993).
pubmed: 7694675
Wang, J. et al. VSIG-3 as a ligand of VISTA inhibits human T-cell function. Immunology 156, 74–85 (2019).
pubmed: 30220083
Mehta, N. et al. Structure and functional binding epitope of V-domain Ig suppressor of T cell activation. Cell Rep. 28, 2509–2516 (2019).
pubmed: 31484064
Yoon, K. W. et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 349, 1261669 (2015).
pubmed: 26228159 pmcid: 5215039
Somers, W. S., Tang, J., Shaw, G. D. & Camphausen, R. T. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe
pubmed: 11081633
Ahn, E. et al. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl Acad. Sci. USA 115, 4749–4754 (2018).
pubmed: 29654146
Lonberg, N. Human antibodies from transgenic animals. Nat. Biotechnol. 23, 1117–1125 (2005).
pubmed: 16151405
Roberts, R. W. & Szostak, J. W. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl Acad. Sci. USA 94, 12297–12302 (1997).
pubmed: 9356443
Kurz, M., Gu, K. & Lohse, P. A. Psoralen photo-crosslinked mRNA–puromycin conjugates: a novel template for the rapid and facile preparation of mRNA–protein fusions. Nucleic Acids Res. 28, E83 (2000).
pubmed: 10982894 pmcid: 110755
Xu, L. et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem. Biol. 9, 933–942 (2002).
pubmed: 12204693
Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
pubmed: 10742152
Chao, G., Cochran, J. R. & Wittrup, K. D. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J. Mol. Biol. 342, 539–550 (2004).
pubmed: 15327953
Oliphant, T. et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80, 12149–12159 (2006).
pubmed: 17035317 pmcid: 1676294
Kowalsky, C. A. et al. Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing. J. Biol. Chem. 290, 26457–26470 (2015).
pubmed: 26296891 pmcid: 4646304
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
pubmed: 20124702
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
pubmed: 20383002
Maestro (Schrödinger, 2019).
Frei, A. P., Moest, H., Novy, K. & Wollscheid, B. Ligand-based receptor identification on living cells and tissues using TRICEPS. Nat. Protoc. 8, 1321–1336 (2013).
pubmed: 23764939

Auteurs

Robert J Johnston (RJ)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA. robert.johnston@bms.com.

Linhui Julie Su (LJ)

Selection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.

Jason Pinckney (J)

Biomolecular Characterization, Bristol-Myers Squibb, Cambridge, MA, USA.

David Critton (D)

Molecular Structure and Design, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Eric Boyer (E)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Arathi Krishnakumar (A)

Proteomics Discovery, Bristol-Myers Squibb, Hopewell, NJ, USA.

Martin Corbett (M)

Protein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Andrew L Rankin (AL)

Immuno-Oncology Discovery, Five Prime Therapeutics, South San Francisco, CA, USA.

Rose Dibella (R)

Selection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.

Lynne Campbell (L)

Selection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.

Gaelle H Martin (GH)

genOway, Lyon, France.

Hadia Lemar (H)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Thomas Cayton (T)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Richard Y-C Huang (RY)

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Xiaodi Deng (X)

Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Akbar Nayeem (A)

Molecular Structure and Design, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Haibin Chen (H)

Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Burce Ergel (B)

Protein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Joseph M Rizzo (JM)

Protein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Aaron P Yamniuk (AP)

Protein Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Sanjib Dutta (S)

Biomolecular Characterization, Bristol-Myers Squibb, Cambridge, MA, USA.

Justine Ngo (J)

Translational Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Andrea Olga Shorts (AO)

Translational Sciences, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Radha Ramakrishnan (R)

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Alexander Kozhich (A)

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Jim Holloway (J)

Translational Bioinformatics, Bristol-Myers Squibb, Redwood City, CA, USA.

Hua Fang (H)

Lead Discovery and Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Ying-Kai Wang (YK)

Lead Discovery and Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Zheng Yang (Z)

Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Lawrenceville, NJ, USA.

Kader Thiam (K)

genOway, Lyon, France.

Ginger Rakestraw (G)

Selection Technologies and Protein Engineering, Bristol-Myers Squibb, Cambridge, MA, USA.

Arvind Rajpal (A)

Protein Therapeutics and Biologics Lead Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Paul Sheppard (P)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Michael Quigley (M)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Keith S Bahjat (KS)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.

Alan J Korman (AJ)

Immuno-Oncology Discovery, Bristol-Myers Squibb, Redwood City, CA, USA.
Vir Biotechnology, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH